Van beleggers
voor beleggers
desktop iconMarkt Monitor

Ontvang nu dagelijks onze kooptips!

word abonnee


  • 0,030 26 jan 2023 17:31
  • 0,000 (0,00%) Dagrange 0,029 - 0,030
  • 6.908.997 Gem. (3M) 4,4M

Relief therapeutics Holding

9.093 Posts
Pagina: «« 1 ... 396 397 398 399 400 ... 455 »» | Laatste | Omlaag ↓
  1. RodgerRodger 16 mei 2021 13:46
    Relief Therapeutics Holding AG is the largest company from today’s picks ($600+ million market cap), and we still think it’s the most undervalued from this list.

    We first discussed RLFTF in August last year, sharing our bullish stance on the OTC stock. The company did really well in the following months, but its share price eventually started to correct, and RLFTF is currently trading at 20 cents. Nevertheless, we treat his as a consolidation period and think that Relief Therapeutics has strong fundamentals.

    Undervalued OTC stocks RLFTF

    RLFTF’s main product is a compound that it promotes as RLF-100TM (aviptadil), which the company proposes in the treatment of COVID-19-related lung injury. At the end of April, Relief Therapeutics and German-based AdVita Lifescience GmbH announced the start of the phase 2 trial to assess the efficiency of RFL-100TM for the prevention of COVID-19-induced acute respiratory distress syndrome (ARDS).

    The trial (NCT 04536350) is a randomized, double-blind, placebo-controlled phase 2 trial that is carried out at several clinical sites in Switzerland. The study will enroll 80 patients, who will receive either RLF-100 together with standard of care or placebo plus standard of care.

    Prof. Dr. Joerg D. Leuppi, M.D., Ph.D., lead investigator of the study, explained:
  2. RodgerRodger 17 mei 2021 07:37
    Dear Sir or Madam,

    We would like to draw your attention to the following press release of RELIEF THERAPEUTICS Holding AG:

    Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray

    Geneva, Switzerland, May 17, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF)(“Relief”), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat COVID-19-induced lung injury, is pleased to see the recent announcement by APR Applied Pharma Research S.A. ("APR") regarding the initiation of a pivotal clinical trial with its novel nasal spray, temporarily codenamed APR-AOS2020, a Class III medical device, in patients with mild COVID-19. The trial is designed to evaluate the efficacy and safety of the product in reducing viral load in the upper respiratory airways in recently infected individuals. The APR press release can be found here.

    “We are very happy to see the start of this pivotal clinical trial with one of the main product candidates in APR’s portfolio so shortly after we signed the binding term sheet to acquire all shares of this exciting company,” Jack Weinstein, Chief Financial Officer and Treasurer of Relief, said. “We strongly believe that the acquisition of APR will fit perfectly with Relief's strategy to expand our clinical pipeline as it will add synergistic and promising late-stage candidates to treat various indications in rare or debilitating diseases with high unmet medical needs, in addition to marketed products. We are very much looking forward to working with APR and advance our joined product pipeline as quickly as possible to reach patients.”

    Relief and APR, a privately held Swiss pharmaceutical company with over 25 years’ experience in identifying, developing and commercializing known molecules engineered with drug delivery systems in niche and rare diseases on a global basis, announced on May 4, 2021 that the companies had signed a binding term sheet for Relief to acquire all outstanding shares of APR. See “Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR.” For a period of 60 days, Relief has the exclusive right to negotiate and close the transaction on the basis of the terms and conditions in the signed Term Sheet. With APR’s products already on the market, the acquisition will provide Relief with commercial revenues and provide access to an established commercial organization in key European markets that Relief hopes to leverage for other programs. In addition, Relief will gain a robust clinical portfolio in rare or debilitating diseases with high unmet medical need that is synergistic with Relief’s current development pipeline.


    Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief’s lead drug candidate RLF-100TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease.

    RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.

    For more information, visit

    Follow us on LinkedIn

    Raghuram (Ram) Selvaraju, Ph.D., MBA
    Chairman of the Board

    MC Services AG
    Anne Hennecke / Brittney Sojeva
    Tel.: +49 (0) 211-529-252-14

    Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether Relief's acquisition of APR will be completed; (ii) whether any of the drugs in APR's or Relief's pipeline will be approved for commercialization; (iii) whether the acquisition of APR, if completed, will be accretive to Relief; (iv) whether the combined companies will be successful; and (v) those other risks reported in Relief's public filings, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

    +++ End of press release +++

    Should you have any questions or would like to receive further information, please do not hesitate to contact us.

    Best regards,

    Laurie Doyle
    MC Services AG
    phone: +1 347 804 6686
  3. forum rang 10 DeZwarteRidder 17 mei 2021 08:01
    Relief begint steeds meer op Pharming te lijken met dat verschil dat Pharming een flinke winst maakt en Relief de komende 10 tot 20 jaar verlies blijft maken.

    Relief heeft dankzij de corona-crisis een kleine kans gekregen op succes en die kans is niet benut.
    Nu de coronacrisis op z'n laatste benen loopt gaan we weer terug naar normaal en naar een koers die de werkelijke waarde van Relief weergeeft.

    En dat is geen prettig vooruitzicht voor de verstokte fans.

  4. Gerardke 17 mei 2021 08:53

    DeZwarteRidder schreef op 17 mei 2021 08:01:

    Relief begint steeds meer op Pharming te lijken met dat verschil dat Pharming een flinke winst maakt en Relief de komende 10 tot 20 jaar verlies blijft maken.

    Relief heeft dankzij de corona-crisis een kleine kans gekregen op succes en die kans is niet benut.
    Nu de coronacrisis op z'n laatste benen loopt gaan we weer terug naar normaal en naar een koers die de werkelijke waarde van Relief weergeeft.

    En dat is geen prettig vooruitzicht voor de verstokte fans.

    Nu de coronacrisis op z'n laatste benen loopt ??
    Geloof je dit nu zelf ?
    Het moet nog beginnen ;-)
    er gaan enkel minder mensen sterven .. that's it !! Zolang de ganse wereldbevolking niet gevaccineerd is , is Covid niet weg !

    i quote Boris Johnson :
    We worden ook geconfronteerd met de dreiging van nieuwe varianten, en als ze besmettelijker blijken te zijn en de vaccins weten te omzeilen, is er mogelijk een nog groter lijden op komst.”
    In een opvallend sombere verklaring stelde hij dat “het einde van de lockdown niet het einde van de coronapandemie betekent”.
  5. Gerardke 17 mei 2021 09:22
    ik hoop het van harte want ben het echt beu , maar 1 besmettelijke variant die door bescherming gaat van vaccin en we hebben catastrofe , geen enkele regering gaat op tijd reageren !

    wat Relief betreft "als" ze goedkeuring krijgen voor Aviptadil en inhaler ,hebben ze in de toekomst wel een middel voor zowel milde symptomen als IC-patiënten. Wat ze waard zijn laat ik in het midden maar toch meer dan wat ze nu genoteerd staan . SP , rond 0.18 is toch bodem denk ik ..
  6. Gerardke 18 mei 2021 15:28
    Het is niet dat er geld van Acer, Arp , Neurorx in Relief gestoken wordt , dus moneypit is niet van toepassing denk ik . Het is eerder het geld van Relief dat in de andere gaat.
    is geen afleiding want staat al lang in hun pipeline , de resultaten zijn goed dus komt er eerder weer geld binnen , zou nog eerder zeggen dat ze hierdoor hun aanvraag kunnen doen naar Nasdaq
    en hoe het afloopt met Neurorx zullen we in de komende weken wel zien .. hoop dat ik gelijk heb en dat je dan nog eens langskomt ;-) Ze hebben de meeste hier al gemute voor jou denk ik , want er is niemand die nog op je berichten reageert ofwel zijn ze slimmer als ik ;-) dat deel lukt wel maar denk wel dat de meesten hun aandelen nog hebben en erin geloven , dus dat is wellicht niet gelukt ;-)
  7. forum rang 10 DeZwarteRidder 20 mei 2021 14:52
    Van het Yahoo forum:

    New Antiviral Drug Developed With 99.9 Per Cent Efficacy Against COVID-19

    An international team of scientists, from Australia and the US, has developed an experimental direct-acting antiviral therapy drug that can reduce the viral load by 99.9 per cent and can potentially be a new treatment against COVID-19.

    Traditional antivirals, which include Tamiflu, zanamivir and remdesivir, reduce symptoms and help people recover earlier.

    The new antiviral approach used gene-silencing RNA technology called siRNA (small-interfering RNA) to attack the virus' genome directly, which stops the virus from replicating. This approach also uses lipid nanoparticles designed at Griffith University and the City of Hope to deliver the siRNA to the lungs, the critical site of infection.

    "Treatment with virus-specific siRNA reduces viral load by 99.9 per cent. These stealth nanoparticles can be delivered to a wide range of lung cells and silence viral genes," said co-lead researcher Nigel McMillan, Professor at Menzies Health Institute Queensland (MHIQ) at Griffith University.

    When tested in SARS-Cov-2 infected mice the treatment with the therapy improved survival chances. Remarkably, in treated survivors, no virus could be detected in the lungs, the findings published in the journal Molecular Therapy, reported.

    "This treatment is designed to work on all beta coronaviruses such as the original SARS virus (SARS-CoV-1) as well as SARS-CoV-2 and any new variants that may arise in the future because it targets ultra-conserved regions in the virus' genome," added Kevin Morris, Professor and associate director of the Center for Gene Therapy at City of Hope.

    Further, the researchers also showed that the nanoparticles are stable at 4°C for 12 months and at room temperature for greater than one month. This means that this agent could be used in low-resource settings to treat infected patients.

    Further, the results suggest that siRNA-nanoparticle formulations can be developed as a therapy to treat COVID-19 patients, as well as used for future coronavirus infections by targeting the virus' genome directly.

    "These nanoparticles are scalable and relatively cost-effective to produce in bulk," Morris says.

    Er is ook een link naar de studie:
  8. forum rang 7 Kleintje66 20 mei 2021 19:57

    Gerardke schreef op 20 mei 2021 19:54:


    46.51+27.32 (+142.37%)
    As of 1:52PM EDT. Market open.

    Twee dagen geleden was ik met een relatief klein bedrag ingestapt omdat BRPA zo gedaald was maar nu snel weer eruit. Het is een erg vreemd aandeel en ik geloof niet dat het handel met voorkennis is.
  9. forum rang 7 Kleintje66 20 mei 2021 20:14

    Gerardke schreef op 20 mei 2021 20:08:

    Ik weet niet meer wat te geloven op Yahoo staan er veel wilde theorieën.
    Er is alvast iemand met veel geld die meer weet dan ons. ;-)

    Er zijn ook mensen met minder geld die meer weten dan ik maar echt nieuws om 100% plus te rechtvaardigen moet ik nog zien. Zelfs een eua aanvraag zou dat niet moeten veroorzaken, die verwachten we allemaal.
9.093 Posts
Pagina: «« 1 ... 396 397 398 399 400 ... 455 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum


Koers 0,030   Verschil 0,00 (0,00%)
Laag 0,029   Volume 6.908.997
Hoog 0,030   Gem. Volume 4.434.448
26 jan 2023 17:31
Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.


Het laatste advies leest u als IEX Premium-lid

Ontdek Premium

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links